Ask AI

Experts Discuss Key Topics in Treatment for Newly Diagnosed Multiple Myeloma

Podcast
This activity is available for 0.50 CME/CE credit(s).

Released: October 20, 2026

Expiration: April 19, 2027

See Activity Collection

Listen to expert faculty discuss the evolving role of quadruplet therapy in newly diagnosed multiple myeloma, with an emphasis on treatment selection across transplant-eligible and transplant-ineligible populations, the incorporation of proteasome inhibitors, and the tailoring of treatment intensity. The experts also examine unresolved questions regarding the optimal use of bortezomib, the role of autologous stem cell transplantation in the quadruplet era, and the use of MRD status to inform treatment decisions. Maintenance strategies with lenalidomide alone or in combination with anti-CD38 therapy are also discussed. 

NDMM Therapy

Pre Assessment

Assess your current knowledge and clinical approach before beginning your podcast.
1.

How many people with multiple myeloma do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

Which statement best reflects the current role of ASCT for transplant-eligible patients receiving contemporary quadruplet therapy for NDMM?

4.

A patient with newly diagnosed standard-risk multiple myeloma is treated with anti-CD38 antibody-based quadruplet therapy induction/consolidation and transplant, achieving an sCR but not reaching MRD negativity. The patient starts maintenance therapy with an anti-CD38 antibody plus lenalidomide. How long would you plan to continue anti-CD38 antibody maintenance therapy based on current evidence and expert recommendations, provided the patient achieves MRD negativity?